Elevated levels of insulin-like growth factor-1 (IGF-1) are associated with increased cancer risk and mortality.
Lowering the level of IGF-1 is a promising treatment to prevent its recurrence.
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
This randomized, three-group parallel controlled clinical trial included overweight or obese cancer survivors and randomized them Assigned to 1) self-controlled weight loss group (control group), 2) coach-guided weight loss group or 3) metformin treatment group.
The main outcome of the study was the changes in IGF-1 levels and IGF-1:IGFBP3 molar ratio at six months.
The duration of the test is 12 months.
Among 121 random participants, 79% were women, 46% were African Americans, and the average age was 60 years.
At baseline, the subjects’ average BMI was 35 kg/m 2; the average level of IGF-1 was 72.
9 (SD: 21.
7) ng/ml; the average molar ratio of IGF1:IGFBP3 was 0.
17 (SD: 0.
At 6 months, the weight changes of subjects in the self-directed group, coach-directed group, and metformin treatment group were -1.
0001), and -2.
0001), respectively ).
Compared with the self-directed group, at 3 months, participants in the metformin treatment group had IGF-1 levels (mean change: -5.
50 ng/ml, p=0.
02) and IGF1:IGFBP3 molar ratio (mean change: -0.
011) Significantly reduced.
Obese subjects still significantly reduced IGF-1 levels at 6 months (mean difference in change: -7.
2 ng/ml; 95% CI: -13.
3 to -1.
1), while overweight subjects did not (interaction p=0.
There was no significant difference in weight change between the coaching group and the self-directing group.
At 12 months, there was no difference in the outcome of the study.
This shows that among obese cancer survivors, metformin may have a short-term effect on the reduction of IGF-1, but it will gradually disappear over time .
Original source:Original source:
1210/clinem/dgab266" target="_blank" rel="noopener">Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial .
1210/clinem/dgab266" target="_blank" rel="noopener">Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial
in this message